• Medical_Professionals
• Medical_students
• Nurses

Molecular techniques are creating novel insights into the biology and therapeutic perspectives of AML. Molecular diagnosis allows us to distinguish distinct disease entities and to identify patients with different disease behavior and prognosis. Genomic and epigenetic studies have revealed entirely novel insights into the biology of AML, expanded the genomic landscape in unprecedented depth and discovered functional clues of dysregulation. Thus, these studies have profoundly enhanced our understanding of the pathobiology of the disease and identified major pathways of malignant transformation. These insights also furnish keys to the development of novel specifically acting therapeutic drugs and provide the opportunity to develop more sophisticated risk-adjusted therapeutic approaches.

This Conference on ACUTE MYELOID LEUKEMIA intends to promote informal interaction and ample discussion between scientists and clinicians working in the field. Scientific presentations by international leaders will provide the current status and a perspective of these exciting developments. In separate sessions results from both basic and clinical research will be presented. The target audience will comprise besides key opinion leader scientists, PhD students, basic scientists, physician-scientists, as well as clinicians with an interest in the field.

The program will include:

Plenary Sessions

Discussions and debates

Simultaneous Meet the Expert sessionsPoster sessions

This meeting will be valuable or you if you are looking for:

A cutting-edge scientific program – from basic science to clinical and therapeutic applications and perspectives

Multiple opportunities for scientific interaction with an international faculty of distinguished experts

An emphasis on critical discussion

Learning Objectives

Understand the pathobiology of leukaemia and its development with respect to alterations in hematopoietic stem cells, their microenvironment and altered signal transduction pathways

Acquire insight into the possible mechanisms of preleukaemic disorders and genomic instability that predispose to leukemogenesis and predispose also to disease progression.

Understand about the characterisation of a leukemia stem cell and its relationship to disease development and phenotype

Learn about the pathobiologic importance of epigenetic dysregulation in the development of acute myeloid leukemia (eg, methylation, microRNA) and its clinical impact

Evaluate the merits and relevance of molecular diagnostics and minimal residual disease assessment in relation to various management decisions

Gain insight into novel therapeutics of acute myeloid leukemia, including knowledge about their mechanisms of action, the current developmental status of various targeted drugs and their promises for future clinical application.

EUR

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

Congress Centre in Lisbon

Square Industries

Lisboa, Lisboa, Portugal

Submission Info

Deadline for Abstracts : July 16, 2017 

Deadline for Abstract Review completion: July 23, 2017 

Deadline for Late-breaking abstracts: September 1, 2017 (to be reviewed individually)

Guidelines:

Your abstract has to be structured (eg Objectives, Methods, Results, Conclusions)

Maximum number of words: 400

You abstract will be submitted to the peer review procedure.

Contact No.: + 33(0)1 57 27 68 33

Email: nicolas.jaillard@univ-paris-diderot.fr

Diamond Conference Partner

and

Ruby Conference Partners

and

Supporting Partners

Contact No.: + 33(0)1 57 27 68 33

Email: nicolas.jaillard@univ-paris-diderot.fr